The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Open accessPublished version of a preprint
Abstract
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Impacts of vaccine prioritization strategies on mortality and infections. (A) Distribution of vaccines for five prioritization strategies: under 20 years, adults 20 to 49 years, adults 20+ years, adults 60+ years, and all ages. (B, C, F, and G) Example simulation curves show [(B) and (C)] percentage of the total population infected over time and [(F) and (G)] cumulative mortality for no vaccines (gray dashed lines) and for five different prioritization strategies [colored lines matching (A)], with [(B) and (F)] 10% and [(C) and (G)] 30% vaccine supply. (D, E, H, and I) Summary curves show percent reductions in [(D) and (E)] infections and [(H) and (I)] deaths in comparison to an unmitigated outbreak for vaccine supplies between 1 and 50% after 365 days of simulation. Squares and diamonds show how the outputs from single simulations [(F) and (G)] correspond to points in summary curves (H). Gray shading indicates the period during which vaccine is being rolled out at 0.2% of total population per day. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. These simulations assume contact patterns and demographics of the United States (38, 53) and an all-or-nothing, transmission-blocking vaccine with 90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).](https://figures.cochat.ai/paper-figures/040af1c419fe4105805e757ba6eecdfa/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-1.jpg)
![Fig. 2 Mortality-minimizing vaccine prioritization strategies across reproductive numbers R0 and countries. (A to E) Heatmaps show the prioritization strategies that result in maximum reduction of mortality for varying values of [(A) and (B)] the basic reproductive number R0 and [(C), (D), and (E)] across nine countries, for vaccine supplies between 1 and 50% of the total population, for an all-or-nothing and transmission-blocking vaccine, 90% vaccine efficacy. [(A) and (B)] Contact patterns and demographics of the United States (38, 53). [(C), (D), and (E)] Contact patterns and demographics of POL, Poland; ZAF, South Africa; CHN, China; BRA, Brazil; ZWE, Zimbabwe; ESP, Spain; IND, India; USA, United States of America; and BEL, Belgium, with R0 and rollout speeds as indicated.](https://figures.cochat.ai/paper-figures/3232e6d2c98d4491b422e996e35f7beb/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-2.jpg)
![Fig. 3 Effects of age-dependent vaccine efficacy on the impacts of prioritization strategies. (A) Diagram of hypothetical age-dependent vaccine efficacy shows decrease from 90% baseline efficacy to 50% efficacy among individuals aged 80+ years, beginning at age 60 (dashed line). (B and C) Percent reduction in deaths in comparison with an unmitigated outbreak for transmission-blocking all-or-nothing vaccines with either constant 90% efficacy for all age groups (solid lines) or age-dependent efficacy shown in (A) (dashed lines), covering scenario 1 [0.2% rollout per day, R0 = 1.15; (B)] and scenario 2 [0.2% rollout per day, R0 = 1.5 (C)]. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. Shown are contact patterns and demographics of the United States (38, 53); all-or-nothing and transmission-blocking vaccine.](https://figures.cochat.ai/paper-figures/85e54e74290b4a1b82ec5b49b5f8d03f/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-3.jpg)
![Fig. 4 Effects of existing seropositivity on the impacts of prioritization strategies. (A to C) Percent reductions in (A) infections, (B) deaths, and (C) years of life lost (YLL) for prioritization strategies when existing age-stratified seroprevalence is incorporated [August 2020 estimates for New York City; mean seroprevalence 26.9% (28)]. Plots show reductions for scenario 2 (0.2% rollout per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) or to only seronegatives (dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (54), and approximately 3 months of seroreversion (supplementary materials, materials and methods) (29). Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing and transmission-blocking vaccine with 90% vaccine efficacy. Lower and higher seroprevalence examples are provided in figs. S12 and S13, respectively.](https://figures.cochat.ai/paper-figures/4122f4138dc44271af1ce6fd7d40abb0/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaccination alone is not expected to be able to control the spread of the infection, and a carefully planned vaccination campaign25,26 needs to be coordinated with continued implementation of NPIs27 until sufficient coverage is reached to make the case fatality rate (CFR) similar to that of seasonal influenza.”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
COVID-19 and Racial/Ethnic Disparities
Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020) · JAMA · doi:10.1001/jama.2020.8598 · Cited by 2,047 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,759 · cited 1×
“Age-stratified susceptibility values were drawn from literature estimates ( 13 ).”
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh, J. E., Tokuyama, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2700-3 · Cited by 1,459 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China
Zhang, J., Litvinova, M., Liang, Y., Wang, Y., Wang, W., Zhao, S., Wu, Q., Merler, S., Viboud, C., Vespignani, A., et al. (2020) · Science · doi:10.1126/science.abb8001 · Cited by 1,107 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100 · cited 1×
“COVID-19 vaccines may not be equally effective across age groups in preventing infection or transmission, a phenomenon known to affect influenza vaccines ( 23–26 ).”
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · cited 2×
“Serostatus itself is an imperfect indicator of protection, and the relationship of prior infection, serostatus, and protection may change over time (10, 29,32,33).”
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Research works printed but not linked: 1
- K. E. Atkinson An Introduction to Numerical Analysis (Wiley 1989) chap. 2 pp. 56–58 second edn.
Cited by
Goel, R. R., Apostolidis, S. A., Painter, M. M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S., Hicks, P., Meng, W., Rosenfeld, A. M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi6950 · Cited by 655
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study
Moore, S., Hill, E. M., Tildesley, M. J., Dyson, L., & Keeling, M. J. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00143-2 · Cited by 537
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
Müller, L., Andrée, M., Moskorz, W., Drexler, I., Walotka, L., Grothmann, R., Ptok, J., Hillebrandt, J., Ritchie, A., Rabl, D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab381 · Cited by 511
“A recent, thorough study using mathematical 86 modeling to investigate vaccine prioritization strategies supports the preferential 87 vaccination of the elderly [20].”
BackgroundThe changing epidemiology of SARS-CoV-2
Koelle, K., Martin, M. A., Antia, R., Lopman, B., & Dean, N. E. (2022) · Science · doi:10.1126/science.abm4915 · Cited by 295
Understanding COVID-19 vaccine efficacy
Lipsitch, M., & Dean, N. E. (2020) · Science · doi:10.1126/science.abe5938 · Cited by 228
Self-citationJentsch, P. C., Anand, M., & Bauch, C. T. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00057-8 · Cited by 232
Dynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers
Buckner, J. H., Chowell, G., & Springborn, M. R. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025786118 · Cited by 216
“(17) found that prioritizing adults older than 60 y of age is a robust strategy for minimizing deaths.”
BackgroundGiordano, G., Colaneri, M., Di Filippo, A., Blanchini, F., Bolzern, P., De Nicolao, G., Sacchi, P., Colaneri, P., & Bruno, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01334-5 · Cited by 192
Inequality in the distribution of Covid-19 vaccine: a systematic review
Bayati, M., Noroozi, R., Ghanbari-Jahromi, M., & Jalali, F. S. (2022) · International Journal for Equity in Health · doi:10.1186/s12939-022-01729-x · Cited by 178
“(2021), prioritizing vaccination for adults over 60 years of age with underlying disease is an appropriate strategy for reducing mortality from COVID-19 [21].”
BackgroundMatrajt, L., Eaton, J., Leung, T., Dimitrov, D., Schiffer, J. T., Swan, D. A., & Janes, H. (2021) · Nature Communications · doi:10.1038/s41467-021-23761-1 · Cited by 177
A Mathematical Model of COVID-19 with Vaccination and Treatment
Diagne, M. L., Rwezaura, H., Tchoumi, S. Y., & Tchuenche, J. M. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/1250129 · Cited by 182
Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 158
Patel, M. D., Rosenstrom, E., Ivy, J. S., Mayorga, M. E., Keskinocak, P., Boyce, R. M., Lich, K. H., Smith, R., Johnson, K., Delamater, P. L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.10782 · Cited by 141
Transition to endemicity: Understanding COVID-19
Antia, R., & Halloran, M. E. (2021) · Immunity · doi:10.1016/j.immuni.2021.09.019 · Cited by 140
Controlling the pandemic during the SARS-CoV-2 vaccination rollout
Viana, J., van Dorp, C. H., Nunes, A., Gomes, M. C., van Boven, M., Kretzschmar, M., Veldhoen, M., & Rozhnova, G. (2021) · Nature Communications · doi:10.1038/s41467-021-23938-8 · Cited by 149
Anti-spike antibody response to natural SARS-CoV-2 infection in the general population
Wei, J., Matthews, P. C., Stoesser, N. E., Maddox, T., Lorenzi, L., Studley, R., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26479-2 · Cited by 143
Acuña‐Zegarra, M. A., Díaz‐Infante, S., Baca-Carrasco, D., & Olmos‐Liceaga, D. (2021) · Mathematical Biosciences · doi:10.1016/j.mbs.2021.108614 · Cited by 137
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality
Nakanishi, T., Pigazzini, S., Degenhardt, F., Cordioli, M., Butler‐Laporte, G., Maya‐Miles, D., Jiménez, B. N., Bouysran, Y., Niemi, M., Palom, A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152386 · Cited by 130
Vaccine nationalism and the dynamics and control of SARS-CoV-2
Wagner, C. E., Saad-Roy, C. M., Morris, S. E., Baker, R. E., Mina, M. J., Farrar, J., Holmes, E. C., Pybus, O. G., Graham, A. L., Emanuel, E., et al. (2021) · Science · doi:10.1126/science.abj7364 · Cited by 133
Narasimhan, M., Mahimainathan, L., Araj, E., Clark, A. E., Markantonis, J., Green, A. P., Xu, J., SoRelle, J. A., Alexis, C., Fankhauser, K., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00388-21 · Cited by 123
“tatus for prioritizing vaccination (16), and along these lines, the new cutoff range could”
BackgroundYang, J., Marziano, V., Deng, X., Guzzetta, G., Zhang, J., Trentini, F., Cai, J., Poletti, P., Zheng, W., Wang, W., et al. (2021) · Nature Human Behaviour · doi:10.1038/s41562-021-01155-z · Cited by 122
Estimating the impact of COVID-19 vaccine inequities: a modeling study
Gozzi, N., Chinazzi, M., Dean, N. E., Longini, I. M., Halloran, M. E., Perra, N., & Vespignani, A. (2023) · Nature Communications · doi:10.1038/s41467-023-39098-w · Cited by 116
COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
He, Q., Mao, Q., Zhang, J., Bian, L., Gao, F., Wang, J., Xu, M., & Liang, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669339 · Cited by 117
Hodcroft, E. B., Domman, D., Snyder, D. J., Oguntuyo, K. Y., Diest, M. V., Densmore, K. H., Schwalm, K. C., Femling, J., Carroll, J. L., Scott, R. S., et al. (2021) · medRxiv · doi:10.1101/2021.02.12.21251658 · Cited by 119
“Furthermore, seroprevalence surveys indicate that between 1 in 10 and 1 in 3 people in the USA have already been infected with SARS-CoV-2, potentially high enough that selection for immune evasion may be ongoing (Angulo, Finelli and Swerdlow, 2021; Bubar et al. , 2021).”
Alsalem, M. A., Alsattar, H. A., Albahri, A. S., Mohammed, R. T., Albahri, O. S., Zaidan, A. A., Alnoor, A., Alamoodi, A. H., Qahtan, S., Zaidan, B. B., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.08.026 · Cited by 103
“…who support healthcare workers and people who face greater barriers to accessing care if they become seriously ill or those living or working in conditions that place them at risk of infection Reference [17] utilised an informed approach to prioritise vaccines based on age and serological status .”
Retracted(2021) · doi:10.1016/j.vaccine.2021.04.002 · Cited by 101
Swan, D. A., Bracis, C., Janes, H., Moore, M., Matrajt, L., Reeves, D. B., Burns, E., Donnell, D. J., Cohen, M. S., Schiffer, J. T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94719-y · Cited by 100
Plans to Vaccinate Children for Coronavirus Disease 2019: A Survey of United States Parents
Teasdale, C. A., Borrell, L. N., Kimball, S. H., Rinke, M. L., Rane, M. S., Fleary, S. A., & Nash, D. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.07.021 · Cited by 99
“Overall, the findings from our survey suggest that targeted efforts will be needed to ensure high coverage of COVID-19 vaccination in US children.(14) They also show that providing evidence of the safety of vaccines and educating parents about the importance of vaccinating children may help increase acceptability and…”
Biomedical Big Data Technologies, Applications, and Challenges for Precision Medicine: A Review
Yang, X., Huang, K., Yang, D., Zhao, W., & Zhou, X. (2023) · Global Challenges · doi:10.1002/gch2.202300163 · Cited by 117
Han, S., Cai, J., Yang, J., Zhang, J., Wu, Q., Zheng, W., Shi, H., Ajelli, M., Zhou, X., & Yu, H. (2021) · Nature Communications · doi:10.1038/s41467-021-24872-5 · Cited by 98
Shen, M., Zu, J., Fairley, C. K., Pagán, J. A., An, L., Du, Z., Guo, Y., Rong, L., Xiao, Y., Zhuang, G., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.02.056 · Cited by 101
What can we expect from first-generation COVID-19 vaccines?
Peiris, M. J. S., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31976-0 · Cited by 106
Larremore, D. B., Fosdick, B. K., Bubar, K. M., Zhang, S., Kissler, S. M., Metcalf, C. J. E., Buckee, C. O., & Grad, Y. H. (2021) · eLife · doi:10.7554/elife.64206 · Cited by 95
“…of the population that has been infected by, and recovered from, the coronavirus causing COVID-19 will be a critical measure to inform policies on a population level, including when and how social distancing interventions can be relaxed, and the prioritization of vaccines ( Bubar et al., 2021 ).”
Self-citationThe importance of non-pharmaceutical interventions during the COVID-19 vaccine rollout
Gozzi, N., Bajardi, P., & Perra, N. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009346 · Cited by 98
Vaccinating the oldest against COVID-19 saves both the most lives and most years of life
Goldstein, J. R., Cassidy, T., & Wachter, K. W. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026322118 · Cited by 94
Challenges for modelling interventions for future pandemics
Kretzschmar, M., Ashby, B., Fearon, E., Overton, C. E., Panovska‐Griffiths, J., Pellis, L., Quaife, M., Rozhnova, G., Scarabel, F., Stage, H. B., et al. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100546 · Cited by 93
COVID-19 Vaccine: A neutrosophic MCDM approach for determining the priority groups
Hezam, I. M., Nayeem, M. K., Foul, A., & Alrasheedi, A. F. (2020) · Results in Physics · doi:10.1016/j.rinp.2020.103654 · Cited by 89
“[3] used an informed approach to prioritize vaccines based on age and serological status.”
Analisis Sentimen Tweet Vaksin COVID-19 Menggunakan Recurrent Neural Network dan Naïve Bayes
Lestandy, M., Abdurrahim, A., & Syafaah, L. (2021) · Jurnal RESTI (Rekayasa Sistem dan Teknologi Informasi) · doi:10.29207/resti.v5i4.3308 · Cited by 88
“Salah satu upaya tindakan pemerintah akibat persebaran COVID-19 yang begitu cepat yaitu memberikan vaksinasi kepada masyarakat sebagai upaya pencegahan[12], [13].”
BackgroundThe impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries
Duroseau, B., Kipshidze, N. N., & Limaye, R. J. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1087138 · Cited by 87
RETRACTED: Novel dynamic fuzzy Decision-Making framework for COVID-19 vaccine dose recipients
Albahri, O. S., Zaidan, A. A., Albahri, A. S., Alsattar, H. A., Mohammed, R. T., Aickelin, U., Kou, G., Jumaah, F., Salih, M. M., Alamoodi, A. H., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.08.009 · Cited by 85
“Bubar [15] utilised an informed approach to prioritise vaccines based on age and serological status.”
RetractedOptimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea
Shim, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040591 · Cited by 90
“found that in the USA, a transmission-blocking vaccine should be prioritized in younger adults (age 20–49 years) to minimize the cumulative incidence and in people older than 60 years to minimize mortality [18].”
BackgroundMarkovič, R., Šterk, M., Marhl, M., Perc, M., & Gosak, M. (2021) · Results in Physics · doi:10.1016/j.rinp.2021.104433 · Cited by 86
Modelling vaccination strategies for COVID-19
Wagner, C. E., Saad-Roy, C. M., & Grenfell, B. T. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00687-3 · Cited by 83
Interpreting vaccine efficacy trial results for infection and transmission
Lipsitch, M., & Kahn, R. J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.011 · Cited by 88
“This information can inform personal decisions about resuming contact once one has been vaccinated (or one’s contact has), prioritization decisions [13], models of the effect of vaccination [14], and policy [15].”
Self-citationLeung, K. S. M., Wu, J. T. K., & Leung, G. M. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00167-5 · Cited by 79
Youssef, D., Abbas, L. A., Berry, A., Youssef, J., & Hassan, H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264128 · Cited by 82
“Despite that these measures are considered essential in the short term, a long-lasting solution represented by vaccines is urgently needed to dramatically lessen the mortality burden and conceivably halt local transmission [4].”
BackgroundA model and predictions for COVID-19 considering population behavior and vaccination
Usherwood, T., LaJoie, Z., & Srivastava, V. (2021) · Scientific Reports · doi:10.1038/s41598-021-91514-7 · Cited by 74
“[21] accounted for the possibility of ruling out individuals with antibodies from receiving the vaccine using a serological test, and added an age-dependent effectiveness of the vaccine.”
BackgroundWrigley‐Field, E., Kiang, M. V., Riley, A. R., Barbiéri, M., Chen, Y., Duchowny, K. A., Matthay, E. C., Riper, D. C. V., Jegathesan, K., Bibbins-Domingo, K. B., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj2099 · Cited by 74
Bauer, S., Contreras, S., Dehning, J., Linden, M., Iftekhar, E. N., Mohr, S. B., Olivera-Nappa, Á., & Priesemann, V. (2021) · PLoS Comput. Biol. · doi:10.1371/journal.pcbi.1009288 · Cited by 73
Mak, H., Dai, T., & Tang, C. S. (2022) · Production and Operations Management · doi:10.1111/poms.13862 · Cited by 79
“…COVID transmissions depend on the numbers of infectious and susceptible individuals, their transmissibility and susceptibility (which depend on their vaccination status), and the frequencies of social contact between the two age groups as governed by a “contact matrix” (Bubar et al. 2021).”
Importance of COVID-19 vaccine efficacy in older age groups
Sadarangani, M., Raya, B. A., Conway, J. M., Iyaniwura, S. A., Falcão, R. C., Colijn, C., Coombs, D., & Gantt, S. M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.020 · Cited by 70
COVID ‐19: vaccination problems
Brüssow, H. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15549 · Cited by 80
“If infectionminimizing strategies are targeted and not mortality, the model recommends to prioritize adults 20–49 for vaccination (Bubar et al., 2021; Fitzpatrick and Galvani, 2021).”
BackgroundPublic Knowledge, Attitude, and Perception towards COVID-19 Vaccination in Saudi Arabia
Al-Zalfawi, S. M., Rabbani, S. I., Asdaq, S. M. B., Alamri, A. S., Alsanie, W. F., Alhomrani, M., Mohzari, Y. A., Alrashed, A. A., AlRifdah, A. H., & Almagrabe, T. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910081 · Cited by 70
Mesa, D. O., Hogan, A. B., Watson, O. J., Charles, G. D., Hauck, K., Ghani, A. C., & Winskill, P. (2022) · Communications Medicine · doi:10.1038/s43856-022-00075-x · Cited by 73
Huang, P., Hung, C., Kuo, Y., Chen, Y., Ahorsu, D. K., Yen, C., Lin, C., Griffiths, M. D., & Pakpour, A. H. (2021) · Vaccines · doi:10.3390/vaccines9091046 · Cited by 69
“The low serious infection rate and lack of priority in vaccination uptake may explain the poor intention to get vaccinated against COVID-19 among university students [30,31].”
BackgroundVaccine rollout strategies: The case for vaccinating essential workers early
Mulberry, N., Tupper, P. F., Kirwin, E. M., McCabe, C. J., & Colijn, C. (2021) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000020 · Cited by 69
“Our model is an extension of the framework introduced by Bubar et al [28], but now considers both age and essential worker status; in addition, we explore Long COVID and chronic outcomes.”
BackgroundMethodInfluentialHavervall, S., Ng, H., Falk, A. J., Greilert‐Norin, N., Månberg, A., Marking, U. W., Laurén, I., Gabrielsson, L., Salomonsson, A., Aguilera, K., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13387 · Cited by 66
“These findings may contribute to the scientific ground in vaccine prioritization, such as directing vaccines towards seronegative individuals in countries with vaccine shortage and low vaccine coverage [19].”
The impact of vaccination on the spread of COVID-19: Studying by a mathematical model
Yang, B., Yu, Z., & Cai, Y. (2021) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2021.126717 · Cited by 63
Are, E. B., Song, Y., Stockdale, J. E., Tupper, P. F., & Colijn, C. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111368 · Cited by 63
“This age and contact structured model was presented in Mulberry et al. (2021) and is based on an earlier model of Bubar et al. (2021).”
Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review
Saadi, N., Chi, Y.-L., Ghosh, S., Eggo, R. M., McCarthy, C. V., Quaife, M., Dawa, J., Jit, M., & Vassall, A. (2021) · BMC Medicine · doi:10.1186/s12916-021-02190-3 · Cited by 62
“[40] A few studies investigated the optimal vaccination strategy when maximising QALYs, DALYs or YLLs.”
BackgroundInfluentialChen, J., Hoops, S., Marathe, A., Mortveit, H., Lewis, B. L., Venkatramanan, S., Haddadan, A., Bhattacharya, P., Adiga, A., Vullikanti, A. K. S., et al. (2021) · medRxiv · doi:10.1101/2021.02.04.21251012 · Cited by 62
“[12] identified that under different underlying assumptions, vaccine prioritization policies vary from 20-49 years to adults over 60 years old.”
BackgroundPearson, C. A. B., Bozzani, F. M., Procter, S. R., Davies, N. G. M., Huda, M., Jensen, H. T., Keogh-Brown, M. R., Khalid, M., Sweeney, S., Rueda, S. T., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003815 · Cited by 60
Modeling COVID-19 dynamic using a two-strain model with vaccination
de León, U. A.-P., Avila-Vales, E. J., & Huang, K. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.111927 · Cited by 62
Shahparvari, S., Hassanizadeh, B., Mohammadi, A., Kiani, B., Lau, K. H., Chhetri, P., & Abbasi, B. (2022) · Transportation Research Part E Logistics and Transportation Review · doi:10.1016/j.tre.2021.102598 · Cited by 64
“Prioritisation of accine allocation must be empirically and objectively determined (Bubar et al., 2020).”
Epsi, N. J., Richard, S. A., Lindholm, D. A., Mende, K., Ganesan, A., Huprikar, N., Lalani, T., Fries, A. C., Maves, R. C., Colombo, R. E., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac392 · Cited by 61
Vaccination Prioritization Strategies for COVID-19 in Korea: A Mathematical Modeling Approach
Choi, Y., Kim, J. S., Kim, J. E., Choi, H., & Lee, C. H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18084240 · Cited by 58
Optimizing COVID-19 vaccination programs during vaccine shortages
Liu, K., & Lou, Y. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.02.002 · Cited by 58
Optimizing age-specific vaccination
Fitzpatrick, M. C., & Galvani, A. P. (2021) · Science · doi:10.1126/science.abg2334 · Cited by 58
Padoan, A., Bonfante, F., Cosma, C., Chiara, C. D., Sciacovelli, L., Pagliari, M., Bortolami, A., Costenaro, P., Musso, G., Basso, D., et al. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0313 · Cited by 57
Kiem, C. T., Massonnaud, C., Lévy-Bruhl, D., Poletto, C., Colizza, V., Bosetti, P., Fontanet, A. L., Gabet, A., Olié, V., Zanetti, L. C. D. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101001 · Cited by 61
“For vaccines reducing the severity of the disease, modelling studies have shown that vaccination strategies prioritized towards older individuals may substantially reduce the number of COVID-19 deaths [2 (cid:1) 5] owing to the strong age dependence for severe infections [6,7].”
Modeling how antibody responses may determine the efficacy of COVID-19 vaccines
Padmanabhan, P., Desikan, R., & Dixit, N. M. (2022) · Nature Computational Science · doi:10.1038/s43588-022-00198-0 · Cited by 61
“These include (1) the neutralization potential of individual NAbs, (2) the diversity of the NAb response within and across individuals, (3) the relationship between NAb titers in individuals and their neutralization potential, (4) the within-host dynamics of disease progression, (5) the influence of vaccination on the…”
BackgroundKrueger, T., Gogolewski, K., Bodych, M., Gambin, A., Giordano, G., Cuschieri, S., Czypionka, T., Perc, M., Petelos, E., Rosińska, M., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00084-w · Cited by 60
The effect of COVID-19 vaccination in Italy and perspectives for living with the virus
Marziano, V., Guzzetta, G., Mammone, A., Riccardo, F., Poletti, P., Trentini, F., Manica, M., Siddu, A., Bella, A., Stefanelli, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27532-w · Cited by 61
Ferranna, M., Cadarette, D., & Bloom, D. E. (2021) · Engineering · doi:10.1016/j.eng.2021.03.014 · Cited by 55
On the role of data, statistics and decisions in a pandemic
Jahn, B., Friedrich, S., Behnke, J., Engel, J., Garczarek, U., Münnich, R. T., Pauly, M., Wilhelm, A., Wolkenhauer, O., Zwick, M., et al. (2022) · AStA Advances in Statistical Analysis · doi:10.1007/s10182-022-00439-7 · Cited by 58
“2021) including prediction of the impact of vaccination (Bubar et al. 2021).”
BackgroundPrioritizing COVID-19 vaccination by age
Castro, M. C., & Singer, B. H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103700118 · Cited by 56
The optimal allocation of Covid-19 vaccines
Babus, A., Das, S., & Lee, S. M. (2023) · Economics Letters · doi:10.1016/j.econlet.2023.111008 · Cited by 50
“The allocation of vaccines has also been analyzed in the context of SEIR modeling framework (Bubar et al., 2021; Chen et al., 2020; Matrajt et al., 2021).”
BackgroundInfluentialEvolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies
Rouzine, I. M., & Rozhnova, G. (2023) · Communications Medicine · doi:10.1038/s43856-023-00320-x · Cited by 54
Optimal control of the spatial allocation of COVID-19 vaccines: Italy as a case study
Lemaitre, J. C., Pasetto, D., Zanon, M., Bertuzzo, E., Mari, L., Miccoli, S., Casagrandi, R., Gatto, M., & Rinaldo, A. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010237 · Cited by 49
“Roll-out strategies are conventionally based on the prioritization of individuals at risk, such as health workers and elderly people [12–15].”
BackgroundMethodUnderstanding hesitancy with revealed preferences across COVID-19 vaccine types
Kutasi, K., Koltai, J., Szabó‐Morvai, Á., Röst, G., Karsai, M., Bíró, P., & Lengyel, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-15633-5 · Cited by 49
“Pfizer Moderna AstraZeneca Sputnik Sinopharm Variance Mean Min Max Any (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) Age x x x x x x Female x x x City Cat.”
Incerti, D., Rizzo, S., Li, X., Lindsay, L., Yau, V., Keebler, D., Chia, J., & Tsai, L. W. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047121 · Cited by 49
Strategic COVID-19 vaccine distribution can simultaneously elevate social utility and equity
Chen, L., Xu, F., Han, Z., Tang, K., Hui, P., Evans, J. A., & Li, Y. (2022) · Nature Human Behaviour · doi:10.1038/s41562-022-01429-0 · Cited by 61
“In COVID-19 vaccine distribution, the most recent studies have focused on the trade-off between minimizing the years of life lost and minimizing the number of lives lost 23–27 , both of which reflect social-utility-oriented values and neglect disparities across the population.”
BackgroundAdapting Serosurveys for the SARS-CoV-2 Vaccine Era
Duarte, N., Yanes‐Lane, M., Arora, R. K., Bobrovitz, N., Liu, M., Bego, M. G., Yan, T., Cao, C., Gurry, C., Hankins, C. A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab632 · Cited by 46
“nated populations, which may improve the marginal impact of each dose ([13]).”
Park, H. J., Gonsalves, G., Tan, S. T., Kelly, J. D., Rutherford, G. W., Wachter, R. M., Schechter, R., Paltiel, A. D., & Lo, N. C. (2024) · Nature Communications · doi:10.1038/s41467-024-45549-9 · Cited by 47
“Most of the estimated bene fi t from more frequent booster vaccination occurred in older age groups, the immunocompromised, and those without prior COVID-19, which is consistent with prior literature analyzing vaccine prioritization during the introduction of COVID-19 vaccines 9,10,13 .”
BackgroundResultFuady, A., Nuraini, N., Sukandar, K. K., & Lestari, B. W. (2021) · Vaccines · doi:10.3390/vaccines9050462 · Cited by 47
“Given the higher mortality in the elderly group, the COVID-19 vaccine should be equally allocated, and the elderly should be prioritized [1,18].”
BackgroundModeling the impact of racial and ethnic disparities on COVID-19 epidemic dynamics
Ma, K. C., Menkir, T. F., Kissler, S. M., Grad, Y. H., & Lipsitch, M. (2021) · eLife · doi:10.7554/elife.66601 · Cited by 47
Self-citationModelling the impact of delaying vaccination against SARS-CoV-2 assuming unlimited vaccine supply
Amaku, M., Covas, D. T., Coutinho, F. A. B., Azevedo, R. S., & Massad, E. (2021) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-021-00143-0 · Cited by 45
Risk factor targeting for vaccine prioritization during the COVID-19 pandemic
Chapman, L. A. C., Shukla, P. D., Rodríguez-Barraquer, I., Shete, P. B., León, T. M., Bibbins-Domingo, K. B., Rutherford, G. W., Schechter, R., & Lo, N. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-06971-5 · Cited by 45
“20–29 5,539,817 (15) 66,000 (16) 79 (1) 4600 (3)”
COVID-19 in Asia: Transmission factors, re-opening policies, and vaccination simulation
Baniasad, M., Mofrad, M. G., Bahmanabadi, B., & Jamshidi, S. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111657 · Cited by 45
“Several studies have reported the significant impact of the vaccination on reducing the COVID-19 transmission and prioritizing vaccine allocations (Bubar et al., 2021; Mukandavire et al., 2020; Yang et al., 2020).”
Kemp, F., Proverbio, D., Aalto, A., Mombaerts, L., d’Hérouël, A. F., Husch, A., Ley, C., Gonçalves, J. M., Skupin, A., & Magni, S. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110874 · Cited by 49
Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries
Siedner, M. J., Alba, C., Fitzmaurice, K. P., Gilbert, R. F., Scott, J. A., Shebl, F. M., Ciaranello, A. L., Reddy, K. P., & Freedberg, K. A. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac243 · Cited by 45
Justice in COVID-19 vaccine prioritisation: rethinking the approach
Rhodes, R. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2020-107117 · Cited by 43
Agent-based modelling of reactive vaccination of workplaces and schools against COVID-19
Faucher, B., Assab, R., Roux, J., Lévy-Bruhl, D., Kiem, C. T., Cauchemez, S., Zanetti, L. C. D. S., Colizza, V., Boëlle, P., & Poletto, C. (2022) · Nature Communications · doi:10.1038/s41467-022-29015-y · Cited by 43
Jahn, B., Sroczynski, G., Bicher, M., Rippinger, C., Mühlberger, N., Santamaria, J., Urach, C., Schomaker, M., Stojkov, I., Schmid, D., et al. (2021) · Vaccines · doi:10.3390/vaccines9050434 · Cited by 42
“3), vaccine efficacy 80% or below, and 90% or higher transmission blocking” and “vaccines with very low efficacy in older adults, very high efficacy in younger adults, and declines in efficacy starting at 49 or 59, for a leaky vaccine” [40].”
BackgroundDisease spreading modeling and analysis: a survey
Guzzi, P. H., Petrizzelli, F., & Mazza, T. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac230 · Cited by 54
Modeling waning and boosting of COVID-19 in Canada with vaccination
Childs, L. M., Dick, D. W., Feng, Z., Heffernan, J. M., Li, J., & Röst, G. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100583 · Cited by 44
Modeling the COVID-19 pandemic: a primer and overview of mathematical epidemiology
Saldaña, F., & Velasco‐Hernández, J. X. (2021) · SeMA Journal · doi:10.1007/s40324-021-00260-3 · Cited by 39
“[12] is an age-structured SEIR model with a force of infection, λi , for a susceptible individual in age group i given as follows:”
BackgroundInfluentialA mathematical model for equitable in-country COVID-19 vaccine allocation
Balcik, B., Yucesoy, E., Akca, B., Karakaya, S., Gevsek, A. A., Baharmand, H., & Sgarbossa, F. (2022) · International Journal of Production Research · doi:10.1080/00207543.2022.2110014 · Cited by 39
“…Chandra 2021), designing rollout processes for multi-dose vaccines (e.g. Mak, Dai, and Tang 2021), developing prioritisation measures (e.g. Sahinyazan and Araz 2022), and sequencing the priority groups (e.g. Chen et al. 2020; Foy et al. 2021; Bubar et al. 2021; Li, Bjørnstad, and Stenseth 2021).”
BackgroundMethodSARS-CoV-2 transmission across age groups in France and implications for control
Kiem, C. T., Bosetti, P., Paireau, J., Crépey, P., Salje, H., Lefrancq, N., Fontanet, A. L., Benamouzig, D., Boëlle, P., Desenclos, J. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27163-1 · Cited by 43
COVID-19 and the Paradox of Scientific Advice
Pamuk, Z. (2021) · Perspectives on Politics · doi:10.1017/s1537592721001201 · Cited by 38
Metadata
- Authors
- Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B.
- Affiliations
- University of Colorado Boulder (US)
- Harvard University (US)
- University of Chicago (US)
- Corresponding author
- Bubar, Kate M.
- Larremore, Daniel B.
- ORCID
- Venue
- Science
- Published
- 2021-02-26
- Volume
- 371
- Issue
- 6532
- Pages
- 916-921
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963218
- OpenAlex
- W3123021790
- Cited by
- 775
- References
- 45
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 87 · 2023: 109 · 2022: 222 · 2021: 261
- FWCI
- 65.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- ImmPort
- University of Chicago (cc-by)
- Funders
- National Institutes of Health (3U24GM132013-02S2)
- Morris-Singer Fund
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccine prioritization, SARS-CoV-2, serostatus, serological testing, transmission-blocking vaccine, vaccine inequity, cumulative incidence, mortality, years of life lost, naturally acquired immunity, vaccine supply
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.